Condition
    Effectiveness 3/5

    Omega-3 Fatty Acids for Cardiovascular Disease

    Omega-3s reliably lower triglycerides, and high-dose prescription EPA reduced cardiovascular events in one major trial — but standard fish oil supplements have not shown clear event reduction in large trials.

    Overview

    Omega-3s reliably lower triglycerides, and high-dose prescription EPA reduced cardiovascular events in one major trial — but standard fish oil supplements have not shown clear event reduction in large trials.

    Verdict

    Mixed evidence

    How It Works

    EPA and DHA lower triglycerides via reduced hepatic VLDL production, and may have anti-inflammatory and plaque-stabilizing effects. The clinical translation of these effects has proven inconsistent.

    Dosing & Protocol

    Typical dose

    Recommended dose
    1000 mg combined EPA+DHA daily for general use; 2-4 g/day prescription-grade only under medical supervision for high triglycerides
    Expected timeframe
    Triglycerides fall within 4-8 weeks; event-level benefit is measured over years

    Protocol

    form
    Triglyceride-form fish oil; prescription icosapent ethyl is the form used in the trial that showed cardiovascular benefit
    duration
    Long-term, as part of overall risk management
    co factor
    Take with dietary fat. Evidence is mixed and must be stated plainly: large trials of standard-dose fish oil (VITAL, ASCEND) found no reduction in major cardiovascular events, while REDUCE-IT using 4 g/day icosapent ethyl in statin-treated patients with raised triglycerides did show benefit. Over-the-counter fish oil is not equivalent.
    titration
    Do not self-escalate above 2 g/day - the 4 g/day regimens were prescription-supervised
    starting dose
    1000 mg combined EPA+DHA daily with a meal

    Evidence

    What the studies say

    REDUCE-IT found high-dose icosapent ethyl (4 g/day prescription EPA) cut cardiovascular events by 25% in high-risk statin-treated patients, but STRENGTH with an EPA/DHA formulation showed no benefit, and mineral-oil-placebo concerns complicate interpretation. Large trials of over-the-counter fish oil (VITAL, ASCEND) found no significant reduction in major cardiovascular events. High doses also modestly raise atrial fibrillation risk. Statins, blood pressure control, and exercise remain the load-bearing interventions.

    Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer (VITAL)

    Score: 10/10
    2019
    rct
    n=25871

    Manson JE, Cook NR, Lee IM +3 more

    Supplementation with n-3 fatty acids did not result in a lower incidence of major cardiovascular events or cancer than placebo.

    View source

    Omega-3 fatty acids for cardiovascular disease prevention

    Score: 10/10
    2020
    systematic_review
    n=162796

    Abdelhamid, A.S., Brown, T.J., Brainard, J.S.

    Increasing EPA and DHA has little or no effect on all-cause mortality and cardiovascular events.

    View source

    Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease

    Score: 10/10
    2020
    meta_analysis

    Abdelhamid AS, Brown TJ, Brainard JS +8 more

    Increasing alpha-linolenic acid intake probably makes little or no difference to all-cause mortality or cardiovascular events, with possible small reductions in cardiovascular mortality and arrhythmia

    View source

    Efficacy and Safety of Omega-3 Fatty Acids in the Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis

    Score: 7/10
    2024
    systematic_review

    Yan J, et al.

    Moderate evidence showed that the use of omega-3 fatty acids may reduce the risk of major cardiovascular events, myocardial infarction, and cardiovascular death, but the potential risk of atrial fibrillation and bleeding cannot be ignored.

    View source

    Comparing the cardiovascular risk-reducing effects of polyunsaturated fatty acids in fish oil and krill oil: a network meta-analysis

    Score: 7/10
    2024
    meta_analysis
    0

    Nguyen TT, Mafruhah OR, Huynh TTL

    Krill oil lowered triglycerides and LDL cholesterol comparably to fish oil, with a possible advantage on LDL, though effect sizes were small.

    View source

    Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis

    Score: 9/10
    2019
    meta_analysis
    n=127477

    Hu Y, Hu FB, Manson JE

    Marine omega-3 supplementation was associated with lowered risk of myocardial infarction and coronary heart disease death.

    View source

    Safety

    Caveats

    Fish oil does not replace statins, blood-pressure treatment or smoking cessation, which carry the evidence. Safety ceiling: doses above 3 g/day need medical supervision - high-dose omega-3 increases atrial fibrillation risk and bleeding risk, especially with warfarin, DOACs, aspirin or clopidogrel; stop before surgery. Standard doses are acceptable in pregnancy; avoid cod liver oil because of vitamin A. Chest pain or new breathlessness is an emergency, not a supplement question.

    Less likely to help if

    People with normal triglycerides and controlled risk factors, in whom the large trials showed no event reduction.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.